EFFECTS OF CEFOPERAZONE ON RESPIRATORY INFECTIONS OF THE PATIENTS OF ADVANCED AGE AND/OR WITH UNDERLYING RESPIRATORY DISEASES

• Published in: Japanese journal of antibiotics 1986/03/25, Vol.39(3), pp.679-685
• Main Authors: MOTOJIMA, SHINJI, NUMAO, TOSHIO, WATANABE, SHIGEO, ANDO, NAOHIKO, KURUSU, HIROSHI, OTSUKA, TOMOHIRO, TODA, MASAO, YAMAI, TAKAO, YAMADA, GORO, YUKAWA, TATSUO, FUKUDA, TAKESHI, IKEMORI, RYOSUKE, MAKINO, SOHEI, AMAGAI, MASAHIRO, ISHII, HIKARU, OHASHI, YUJI, KANEKO, YUICHI, MIZUNO, HIDEAKI, KOIZUMI, KAZUHIRO
• Format: Article
• Language: Japanese
• Subjects: Adult; Aged; Bacterial Infections - complications; Bacterial Infections - drug therapy; Cefoperazone - therapeutic use; Female; Humans; Lung Diseases - complications; Male; Microbial Sensitivity Tests; Middle Aged; Respiratory Tract Infections - complications; Respiratory Tract Infections - drug therapy
• ISSN: 0368-2781; 2186-5477
• DOI: 10.11553/antibiotics1968b.39.679

Respiratory infections of 19 subjects of advanced age and/or with underlying respiratory diseases were treated with cefoperazone (CPZ) and its clinical effects were studied. Sixteen subjects suffered from respiratory tract infection and 3 subjects had pneumonia. The age of the subjects ranged from 39 to 77 years with the mean of 63.8, 7 of them being more than 70 years of age. The underlying respiratory diseases included chronic pulmonary emphysema in 6 subjects, diffuse panbronchiolitis in 3, bronchiectasis in 3, silicosis in 2 and one each of chronic bronchitis, pulmonary fibrosis, lung cancer and old pulmonary tuberculosis. One case, 75 years of age, had renal insufficiency. The daily dose of CPZ was 4 grams in 18 of the 19 subjects and the duration of administration ranged 5 to 22 days. The remaining 1 subject received 2 g of CPZ daily for 6 days. Clinical effects were judged from the changes in fever, cough, amount of sputum, dyspnea, rales, cyanosis, chest X-ray, white blood cell counts, CRP, erythrocyte sedimentation rates and results of sputum culture. Clinical effects were good in 16 subjects, fair in 1, and poor in 2. Bacteriological follow-up was carried out in 13 subjects. Infecting bacteria were eliminated from 5 subjects, reduced in 2 and, in 4 subjects, they were replaced by other bacteria. In 1 subject, P. aeruginosa was isolated from sputum even after the treatment with CPZ, and in another subject H. influenzae relapsed immediately after the cessation of the CPZ treatment. No side effects were observed except in 1 subject with eosinophilia. No difference in the effect of CPZ was found between subjects more than from 60 years of age and those less than 59. We conclude that CPZ is useful in the treatment of respiratory infections of patients of advanced age and/or with underlying respiratory diseases.